Artesunate and Dihydroartemisinin Inhibit Rabies Virus Replication.
Antiviral
Artemisinin
Artesunate (ART)
Dihydroartemisinin (DHA)
Rabies virus (RABV)
Journal
Virologica Sinica
ISSN: 1995-820X
Titre abrégé: Virol Sin
Pays: Netherlands
ID NLM: 101514185
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
05
08
2020
accepted:
16
11
2020
pubmed:
5
3
2021
medline:
16
10
2021
entrez:
4
3
2021
Statut:
ppublish
Résumé
Rabies is caused by infection of rabies virus (RABV) and remains a serious threat to the global public health. Except for the requirement for cold chain and high cost of human rabies immune globulin, no small molecule drugs are currently available for clinical treatment of rabies. So, it is of great importance to identify novel compounds that can effectively inhibit RABV infection. Artesunate (ART) and dihydroartemisinin (DHA), two derivatives of artemisinin, are widely used for treatment of malaria in adults and children, showing high safety. In this study, we found that both ART and DHA were able to inhibit RABV replication in host cells at a low concentration (0.1 μmol/L). The antiviral effects of ART and DHA were independent of viral strains and cell lines. Pre-treatment with ART or DHA for 2 h in vitro did not affect the viral replication in host cells, implying that ART and DHA neither reduced the viability of RABV directly nor inhibited the binding and entrance of the virus to host cells. Further studies revealed that ART and DHA inhibited RABV genomic RNA synthesis and viral gene transcription. Treatment with ART or DHA (5 mg/kg) by intramuscular injection improved, to some extent, the survival rate of RABV-challenged mice. Combination treatment with derivatives of artemisinin and mannitol significantly improved the survival rate of RABV-challenged mice. The results suggest that ART and DHA have a great potential to be explored as new anti-rabies agents for treatment of rabies.
Identifiants
pubmed: 33661488
doi: 10.1007/s12250-021-00349-z
pii: 10.1007/s12250-021-00349-z
pmc: PMC7930525
doi:
Substances chimiques
Artemisinins
0
Artesunate
60W3249T9M
artenimol
6A9O50735X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
721-729Informations de copyright
© 2021. Wuhan Institute of Virology, CAS.
Références
Aljabr W, Touzelet O, Pollakis G, Wu W, Munday DC, Hughes M, Hertz-Fowler C, Kenny J, Fearns R, Barr JN, Matthews DA, Hiscox JA (2016) Investigating the influence of ribavirin on human respiratory syncytial virus RNA synthesis by using a high-resolution transcriptome sequencing approach. J Virol 90:4876–4888
pubmed: 26656699
pmcid: 4859727
doi: 10.1128/JVI.02349-15
Auerochs S, Korn K, Marschall M (2011) A reporter system for Epstein–Barr virus (EBV) lytic replication: anti-EBV activity of the broad anti-herpesviral drug artesunate. J Virol Methods 173:334–339
pubmed: 21396962
doi: 10.1016/j.jviromet.2011.03.005
pmcid: 21396962
Banyard AC, Mansfield KL, Wu G, Selden D, Thorne L, Birch C, Koraka P, Osterhaus A, Fooks AR (2019) Re-evaluating the effect of Favipiravir treatment on rabies virus infection. Vaccine 37:4686–4693
pubmed: 29132993
doi: 10.1016/j.vaccine.2017.10.109
pmcid: 29132993
Capci A, Lorion MM, Mai C, Hahn F, Hodek J, Wangen C, Weber J, Marschall M, Ackermann L, Tsogoeva SB (2020) (Iso)Quinoline-Artemisinin hybrids prepared through click chemistry: highly potent agents against viruses. Chemistry 26:12019–12026
pubmed: 32485071
pmcid: 7540715
doi: 10.1002/chem.202001803
D’Alessandro S, Scaccabarozzi D, Signorini L, Perego F, Ilboudo DP, Ferrante P, Delbue S (2020) The use of antimalarial drugs against viral infection. Microorganisms 8:85
pmcid: 7022795
doi: 10.3390/microorganisms8010085
Drouot E, Piret J, Boivin G (2016) Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus. Antivir Ther 21:535–539
pubmed: 26844400
doi: 10.3851/IMP3028
pmcid: 26844400
Du Pont V, Plemper RK, Schnell MJ (2019) Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses. Curr Opin Virol 35:1–13
pubmed: 30753961
doi: 10.1016/j.coviro.2018.12.009
pmcid: 30753961
Du Y, Chen G, Zhang X, Yu C, Cao Y, Cui L (2017) Artesunate and erythropoietin synergistically improve the outcome of experimental cerebral malaria. Int Immunopharmacol 48:219–230
pubmed: 28531845
doi: 10.1016/j.intimp.2017.05.008
pmcid: 28531845
Dufkova L, Sirmarova J, Salat J, Honig V, Palus M, Ruzek D, Fooks AR, Mansfield KL, Tordo N, Jochmans D, Neyts J, Martina B, Koraka P, Osterhaus ADME (2019) Mannitol treatment is not effective in therapy of rabies virus infection in mice. Vaccine 37:4710–4714
pubmed: 29274698
doi: 10.1016/j.vaccine.2017.12.028
pmcid: 29274698
Efferth T (2017) From ancient herb to modern drug: artemisia annua and artemisinin for cancer therapy. Semin Cancer Biol 46:65–83
pubmed: 28254675
doi: 10.1016/j.semcancer.2017.02.009
pmcid: 28254675
Efferth T, Marschall M, Wang X, Huong SM, Hauber I, Olbrich A, Kronschnabl M, Stamminger T, Huang ES (2002) Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J Mol Med (Berl) 80:233–242
doi: 10.1007/s00109-001-0300-8
Franka R, Wu X, Jackson FR, Velasco-Villa A, Palmer DP, Henderson H, Hayat W, Green DB, Blanton JD, Greenberg L, Rupprecht CE (2009) Rabies virus pathogenesis in relationship to intervention with inactivated and attenuated rabies vaccines. Vaccine 27:7149–7155
pubmed: 19925945
doi: 10.1016/j.vaccine.2009.09.034
pmcid: 19925945
Fu ZF (1997) Rabies and rabies research: past, present and future. Vaccine 15(Suppl):S20–S24
pubmed: 9218287
doi: 10.1016/S0264-410X(96)00312-X
pmcid: 9218287
Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer A, Attlan M, Barrat J, Blanton JD, Briggs DJ, Cleaveland S, Costa P, Freuling CM, Hiby E, Knopf L, Leanes F, Meslin F, Metlin A, Miranda ME, Mueller T, Nel LH, Recuenco S, Rupprecht CE, Schumacher C, Taylor L, Natal Vigilato MA, Zinsstag J, Dushoff J (2015) Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis 9:e0003709
pubmed: 25881058
pmcid: 4400070
doi: 10.1371/journal.pntd.0003709
Held J, Supan C, Salazar CLO, Tinto H, Bonkian LN, Nahum A, Moulero B, Sie A, Coulibaly B, Sirima SB, Siribie M, Otsyula N, Otieno L, Abdallah AM, Kimutai R, Bouyou-Akotet M, Kombila M, Koiwai K, Cantalloube C, Din-Bell C, Djeriou E, Waitumbi J, Mordmueller B, Ter-Minassian D, Lell B, Kremsner PG (2015) Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study. Lancet Infect Dis 15:1409–1419
pubmed: 26342427
doi: 10.1016/S1473-3099(15)00079-1
pmcid: 26342427
Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL (2004) Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci USA 101:18105–18110
pubmed: 15601771
pmcid: 539790
doi: 10.1073/pnas.0406927102
Kihira S, Uematsu J, Kawano M, Itoh A, Ookohchi A, Satoh S, Maeda Y, Sakai K, Yamamoto H, Tsurudome M, O’Brien M, Komada H (2014) Ribavirin inhibits human parainfluenza virus type 2 replication in vitro. Microbiol Immunol 58:628–635
pubmed: 25154465
doi: 10.1111/1348-0421.12192
pmcid: 25154465
Kume A, Dang TMA, Shichiri M, Ishida N, Suzuki H (2016) Probucol dramatically enhances dihydroartemisinin effect in murine malaria. Malar J 15:472
pubmed: 27634686
pmcid: 5025592
doi: 10.1186/s12936-016-1532-y
Liu J, Hong X, Lin D, Luo X, Zhu M, Mo H (2017) Artesunate influences Th17/Treg lymphocyte balance by modulating Treg apoptosis and Th17 proliferation in a murine model of rheumatoid arthritis. Exp Ther Med 13:2267–2273
pubmed: 28565837
pmcid: 5443220
doi: 10.3892/etm.2017.4232
Long Y, Yang Q, Xiang Y, Zhang Y, Wan J, Liu S, Li N, Peng W (2020) Nose to brain drug delivery—a promising strategy for active components from herbal medicine for treating cerebral ischemia reperfusion. Pharmacol Res 159:104795
pubmed: 32278035
doi: 10.1016/j.phrs.2020.104795
pmcid: 32278035
Louboutin J, Chekmasova AA, Marusich E, Chowdhury JR, Strayer DS (2010) Efficient CNS gene delivery by intravenous injection. Nat Methods 7:905–909
pubmed: 20953176
doi: 10.1038/nmeth.1518
pmcid: 20953176
Luo Y, Zhang Y, Liu X, Yang Y, Yang X, Zheng Z, Deng X, Wu X, Guo X (2013) Characterization of a wild rabies virus isolate of porcine origin in China. Infect Genet Evol 17:147–152
pubmed: 23567821
doi: 10.1016/j.meegid.2013.03.046
pmcid: 23567821
Luo Z, Tian D, Zhou M, Xiao W, Zhang Y, Li M, Sui B, Wang W, Guan H, Chen H, Fu ZF, Zhao L (2015) lambda-carrageenan P32 is a potent inhibitor of rabies virus infection. PLoS ONE 10:e140586
Luo J, Shi H, Tan Y, Niu X, Long T, Zhao J, Tian Q, Wang Y, Chen H, Guo X (2016a) Two potential recombinant rabies vaccines expressing canine parvovirus virion protein 2 induce immunogenicity to canine parvovirus and rabies virus. Vaccine 34:4392–4398
pubmed: 27449079
doi: 10.1016/j.vaccine.2016.07.020
pmcid: 27449079
Luo J, Zhao J, Tian Q, Mo W, Wang Y, Chen H, Guo X (2016b) A recombinant rabies virus carrying GFP between N and P affects viral transcription in vitro. Virus Genes 52:379–387
pubmed: 26957093
pmcid: 4858564
doi: 10.1007/s11262-016-1313-2
Luo J, Zhang B, Wu Y, Tian Q, Zhao J, Lyu Z, Zhang Q, Mei M, Luo Y, Guo X (2017) Expression of interleukin-6 by a recombinant rabies virus enhances its immunogenicity as a potential vaccine. Vaccine 35:938–944
pubmed: 28089546
doi: 10.1016/j.vaccine.2016.12.069
pmcid: 28089546
Luo J, Zhang Y, He H, Liu Q, Huang S, Guo X (2019) Artesunate enhances the immune response of rabies vaccine as an adjuvant. Vaccine 37:7478–7481
pubmed: 31582270
doi: 10.1016/j.vaccine.2019.09.077
pmcid: 31582270
Luo J, Zhang B, Lyu Z, Wu Y, Zhang Y, Guo X (2020a) Single amino acid change at position 255 in rabies virus glycoprotein decreases viral pathogenicity. Faseb J 34:9650–9663
pubmed: 32469133
doi: 10.1096/fj.201902577R
pmcid: 32469133
Luo J, Zhang B, Wu Y, Guo X (2020b) Amino acid mutation in position 349 of glycoprotein affect the pathogenicity of rabies virus. Front Microbiol 11:481
pubmed: 32308648
pmcid: 7145897
doi: 10.3389/fmicb.2020.00481
Marijon A, Bonnot G, Fourier A, Bringer C, Lavoignat A, Gagnieu MC, Bienvenu AL, Picot S (2014) Efficacy of intranasal administration of artesunate in experimental cerebral malaria. Malar J 13:501
pubmed: 25516091
pmcid: 4320559
doi: 10.1186/1475-2875-13-501
Marosi A, Dufkova L, Forro B, Felde O, Erdelyi K, Sirmarova J, Palus M, Honig V, Salat J, Tikos R, Gyuranecz M, Ruzek D, Martina B, Koraka P, Osterhaus A, Bakonyi T (2019) Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin. Vaccine 37:4724–4735
pubmed: 29805091
doi: 10.1016/j.vaccine.2018.05.066
pmcid: 29805091
Martina BEE, Smreczak M, Orlowska A, Marzec A, Trebas P, Roose JM, Zmudzinski J, Gerhauser I, Wohlsein P, Baumgaertner W, Osterhaus ADME, Koraka P (2019) Combination drug treatment prolongs survival of experimentally infected mice with silver-haired bat rabies virus. Vaccine 37:4736–4742
pubmed: 29843998
doi: 10.1016/j.vaccine.2018.05.065
pmcid: 29843998
Milbradt J, Auerochs S, Korn K, Marschall M (2009) Sensitivity of human herpesvirus 6 and other human herpesviruses to the broad-spectrum antiinfective drug artesunate. J Clin Virol 46:24–28
pubmed: 19501020
doi: 10.1016/j.jcv.2009.05.017
pmcid: 19501020
Musser JM, Heatley JJ, Koinis AV, Suchodolski PF, Guo J, Escandon P, Tizard IR (2015) Ribavirin inhibits parrot bornavirus 4 replication in cell culture. PLoS ONE 10:e134080
doi: 10.1371/journal.pone.0134080
Obeid S, Alen J, Nguyen VH, Pham VC, Meuleman P, Pannecouque C, Le TN, Neyts J, Dehaen W, Paeshuyse J (2013) Artemisinin analogues as potent inhibitors of in vitro hepatitis C virus replication. PLoS ONE 8:e81783
pubmed: 24349127
pmcid: 3859510
doi: 10.1371/journal.pone.0081783
Odaka Y, Xu B, Luo Y, Shen T, Shang C, Wu Y, Zhou H, Huang S (2014) Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells. Carcinogenesis 35:192–200
pubmed: 23929438
doi: 10.1093/carcin/bgt277
pmcid: 23929438
Ramakrishnan MA (2016) Determination of 50% endpoint titer using a simple formula. World J Virol 5:85–86
pubmed: 27175354
pmcid: 4861875
doi: 10.5501/wjv.v5.i2.85
Rogee S, Larrous F, Jochmans D, Ben-Khalifa Y, Neyts J, Bourhy H (2019) Pyrimethamine inhibits rabies virus replication in vitro. Antivir Res 161:1–9
pubmed: 30367894
doi: 10.1016/j.antiviral.2018.10.016
pmcid: 30367894
Romero MR, Efferth T, Serrano MA, Castano B, Macias RI, Briz O, Marin JJ (2005) Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an “in vitro” replicative system. Antivir Res 68:75–83
pubmed: 16122816
doi: 10.1016/j.antiviral.2005.07.005
pmcid: 16122816
Roy A, Hooper DC (2007) Lethal silver-haired bat rabies virus infection can be prevented by opening the blood-brain barrier. J Virol 81:7993–7998
pubmed: 17507463
pmcid: 1951307
doi: 10.1128/JVI.00710-07
Roy A, Phares TW, Koprowski H, Hooper DC (2007) Failure to open the blood-brain barrier and deliver immune effectors to central nervous system tissues leads to the lethal outcome of silver-haired bat rabies virus infection, 1110–1118
Roy S, Mukherjee S, Pawar S, Chowdhary A (2016) Evaluation of In vitro Antiviral Activity of Datura metel Linn. Against rabies virus. Pharmacogn Res 8:265–269
doi: 10.4103/0974-8490.188874
Schnepf N, Corvo J, Pors MJ, Mazeron MC (2011) Antiviral activity of ganciclovir and artesunate towards human cytomegalovirus in astrocytoma cells. Antivir Res 89:186–188
pubmed: 21167209
doi: 10.1016/j.antiviral.2010.12.002
pmcid: 21167209
Smith SP, Wu G, Fooks AR, Ma J, Banyard AC (2019) Trying to treat the untreatable: experimental approaches to clear rabies virus infection from the CNS. J Gen Virol 100:1171–1186
pubmed: 31237530
doi: 10.1099/jgv.0.001269
pmcid: 31237530
Smith TG, Jackson FR, Morgan CN, Carson WC, Martin BE, Gallardo-Romero N, Ellison JA, Greenberg L, Hodge T, Squiquera L, Sulley J, Olson VA, Hutson CL (2020) Antiviral ranpirnase TMR-001 inhibits rabies virus release and cell-to-cell infection in vitro. Viruses 12:177
pmcid: 7077210
doi: 10.3390/v12020177
Smreczak M, Orlowska A, Marzec A, Trebas P, Kycko A, Reichert M, Koraka P, Osterhaus A, Zmudzinski JF (2019) The effect of combined drugs therapy on the course of clinical rabies infection in a murine model. Vaccine 37:4701–4709
pubmed: 29650384
doi: 10.1016/j.vaccine.2018.04.003
pmcid: 29650384
Souza MC, Paixao FH, Ferraris FK, Ribeiro I, Henriques M (2012) Artesunate exerts a direct effect on endothelial cell activation and NF-kappaB translocation in a mechanism independent of plasmodium killing. Malar Res Treat 2012:679090
pubmed: 23097741
pmcid: 3477560
Tan B, Naik H, Jang I, Yu K, Kirsch LE, Shin C, Craft JC, Fleckenstein L (2009) Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects. Malar J 8:304
pubmed: 20021657
pmcid: 2806381
doi: 10.1186/1475-2875-8-304
van Tonder A, Joubert AM, Cromarty AD (2015) Limitations of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay when compared to three commonly used cell enumeration assays. BMC Res Notes 8:47
pubmed: 25884200
pmcid: 4349615
doi: 10.1186/s13104-015-1000-8
Wang L, Liu L, Wang J, Chen Y (2017) Inhibitory effect of artesunate on growth and apoptosis of gastric cancer cells. Arch Med Res 48:623–630
pubmed: 29544887
doi: 10.1016/j.arcmed.2018.03.004
pmcid: 29544887
Wang X, Zheng B, Ashraf U, Zhang H, Cao C, Li Q, Chen Z, Imran M, Chen H, Cao S, Ye J (2020) Artemisinin inhibits the replication of flaviviruses by promoting the type I interferon production. Antivir Res 179:104810
pubmed: 32360948
doi: 10.1016/j.antiviral.2020.104810
pmcid: 32360948
Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A (2016) Efficacy of favipiravir (T-705) in rabies postexposure prophylaxis. J Infect Dis 213:1253–1261
pubmed: 26655300
doi: 10.1093/infdis/jiv586
pmcid: 26655300